Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.
Somatostatin analogues such as octreotide have been shown in experimental systems to exhibit antineoplastic activity. Further laboratory and clinical research is needed to clarify the mechanism of action of somatostatin analogues as antineoplastics, and to determine if the encouraging preclinical results will lead to novel endocrine approaches to the treatment of breast cancer.
Department of Medicine, Jewish General Hospital, Montréal, Québec, Canada.
M
M
Pollak
K
K
Gallant
R
R
Poisson
A
A
Harris
D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood; D013004:Somatostatin / Q000031:analogs & derivatives
D000634:Aminoquinolines; D004958:Estradiol; D013004:Somatostatin; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; C046650:quinagolide; D011388:Prolactin; D015282:Octreotide